Literature DB >> 4082211

Clinical results after therapy with fast neutrons (DT, 14 MeV) since 1976 in Hamburg-Eppendorf.

H D Franke, A Hess, R Schmidt.   

Abstract

In Hamburg since 1976 to 1980 we have treated 328 patients with fast neutron (DT, 14 MeV) and after reconstruction of the generator further 69 patients in 1984. The therapy with DT-neutrons had the best curative effect on high differentiated tumors. With the standard dose of 16 Gy in four weeks or--treating tumors in radiosensitive organs like brain and intestine--with a photon-neutron schedule, we have seen no necroses in normal tissues. The rate of medium or slight subcutaneous fibroses is not more than 10%. The local effect on tumors in our pilot study has been better than with megavoltage therapy in invasive thyroid cancer, prostate cancer stage C, soft tissue sarcoma and also in rectum-carcinoma. The best results have been achieved with neutrons only, but a photon-neutron schedule may be more effective as megavoltage therapy only. With our DT-neutrons we find some indications for better results than with megavoltage therapy if we use sophisticated treatment planning and if we strictly observe the tolerance dose of the different tissues and organs. The therapeutic index of our monoenergetic DT-neutrons is higher than with cyclotron-produced neutrons.

Entities:  

Mesh:

Year:  1985        PMID: 4082211

Source DB:  PubMed          Journal:  Strahlentherapie        ISSN: 0039-2073


  3 in total

1.  Three dimensional conformal neutron radiotherapy for prostate cancer.

Authors:  P J Chuba; R Maughan; J D Forman
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

Review 2.  [Perioperative radiotherapy of bone and soft tissue tumors].

Authors:  H D Franke
Journal:  Langenbecks Arch Chir       Date:  1987

3.  [Results of the treatment with fast neutrons (d.T 13 MeV) in recurrent rectal carcinoma].

Authors:  F J Prott; R Pötter; P Preusser; O Micke; A Schouwink; N Willich
Journal:  Strahlenther Onkol       Date:  1997-06       Impact factor: 4.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.